Injectable Growth Factor Composition for Disc and Connective Tissue Repair

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Chronic low back pain and disability due to internal disc disruption (IDD) and connective tissue injuries remain a significant medical and social problem, with existing treatments like endoscopic surgery being invasive and limited in availability, and current biochemical treatments showing promise but needing further investigation.

Innovation Solution

Injecting a therapeutic composition comprising transforming growth factor beta 1 (TGF-β1) or transforming growth factor beta 2 (TGF-β2), fibroblast growth factor (FGF), and pharmaceutically acceptable excipients such as dextrose, lidocaine, chondroitin, carboxymethyl cellulose, glucosamine, hyaluronic acid, and a buffer into the affected area to stimulate collagen production and repair tissue.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If endoscopic surgery is used to treat internal disc disruption, then pain relief can be achieved, but the treatment is invasive and limited in availability

Engineering Contradiction:

ImprovepainVSAvoidinvasiveness and availability

Core Design Contradiction:

Object-affected harmful factorsVSEase of operation

Solution Approach 1:

The patent replaces the mechanical surgical intervention (endoscopic surgery) with a biochemical treatment system. The therapeutic composition containing TGF-β1/TGF-β2 and FGF is injected directly into the disc, using biological molecules to stimulate tissue repair and reduce pain, thereby eliminating the need for invasive mechanical surgery while maintaining effectiveness.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces a biochemical intermediary substance (therapeutic composition with TGF-β1/TGF-β2 and FGF) that mediates the treatment effect. This intermediary acts as a messenger between the injected solution and the damaged disc tissue, stimulating collagen production and tissue repair without requiring direct mechanical intervention.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If biochemical treatments are used for internal disc disruption, then non-invasive treatment is achieved, but the treatments need further investigation

Engineering Contradiction:

Improvenon-invasivenessVSAvoidneed for further investigation

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent optimizes the parameters of the biochemical treatment by specifying precise concentrations and combinations of TGF-β1/TGF-β2 (1-20 ng/mL) and FGF (50-200 ng/mL) in the therapeutic composition. By controlling these parameters, the treatment achieves reliable and consistent tissue repair effects, reducing the need for further investigation while maintaining non-invasive administration.

Inventive Principle:

Principle #35Parameter changes

3Ease of manufacture

If conventional treatments are used for connective tissue injuries, then existing protocols can be applied, but the treatments are invasive and limited in availability

Engineering Contradiction:

Improvetreatment applicabilityVSAvoidinvasiveness and availability

Core Design Contradiction:

Ease of manufactureVSEase of operation

Solution Approach 1:

The patent creates a universal therapeutic composition that can treat multiple types of connective tissue injuries (tendon, ligament, joint capsule) with a single biochemical formulation. This multi-functional treatment approach eliminates the need for different invasive procedures for different injury types, improving both ease of manufacture and availability while reducing invasiveness.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition significantly reduces pain and promotes tissue repair, offering a less invasive and more widely applicable treatment for IDD and connective tissue injuries, potentially reducing disability and improving quality of life.

Implementation Method 1

The composition comprises transforming growth factor beta 1 (TGF-β1) or transforming growth factor beta 2 (TGF-β2), fibroblast growth factor (FGF), and a pharmaceutically acceptable excipient or a secondary agent

Methodology Applied

Scientific EffectTransforming growth factor beta (TGF-β):

Implementation Method 2

Methodology Applied

Scientific EffectFibroblast growth factor (FGF):

Data Source

PatentUS20250213653A1Treatment of internal disc disruption and connective tissue injuries

Publication Date: 2025.07.03 EEK BJORN

AI summary

This disclosure relates to treating internal disc disruption or a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-β1) or transforming growth factor beta 2 (TGF-β2), fibroblast growth factor (FGF), and a pharmaceutically acceptable excipient or a secondary agent.